Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 5 more

Conditions: Influenza, Human
Interventions: Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1, Comparator 2, Comparator 3; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more

Conditions: Influenza Vaccination
Interventions: Reminders, Financial Incentive, Placebo; Behavioral · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 69,972 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Martinez, California

Conditions: Influenza, COVID-19, Common Cold
Interventions: Immune Support Supplement; Dietary Supplement
Lead sponsor: Center For Interventional Pain and Spine; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Influenza Vaccines
Interventions: Memory for truth; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 26 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Influenza, Healthy Volunteers
Interventions: Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 581 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more

Conditions: Avian Influenza
Interventions: aH5N1c, Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more

Conditions: Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Interventions: Influenza vaccine; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Influenza vaccination; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months and older
Enrollment: 147,494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 187
States / cities: Birmingham, Alabama • Daphne, Alabama • Montgomery, Alabama + 167 more

Conditions: Healthy, no Evidence of Disease
Interventions: cholecalciferol, questionnaire administration, trivalent influenza vaccine; Dietary Supplement · Other · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Influenza
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Haemophilus Influenzae Type B, Carrier State
Interventions: Hib conjugate vaccine (HbOC, Wyeth Vaccines); Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 0 Years and older
Enrollment: 3,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: COVID-19, Influenza A, Influenza Type B, RSV Infection
Interventions: LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test; Diagnostic Test
Lead sponsor: LumiraDx UK Limited; Industry
Eligibility: Not listed
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Cullman, Alabama • Encinitas, California • Miami, Florida + 5 more

Conditions: Influenza, Influenza Immunization
Interventions: Influenza Hemagglutinin mRNA vaccine, Quadrivalent Recombinant Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 20
States / cities: Rolling Hills Estates, California • San Diego, California • Coral Gables, Florida + 14 more

Conditions: Influenza
Interventions: Flufirvitide 3, Placebo for Flufirvitide-3; Drug
Lead sponsor: Autoimmune Technologies, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Hematologic Disorder
Interventions: Lenalidomide, Influenza Vaccine, Pneumovax Vaccine; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic Malignancy, Pediatric Cancer, Transplant-Related Cancer
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Avian Influenza, Immunisation
Interventions: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 47 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Immunology
Interventions: Egg-Based Inactivated Influenza Vaccine, Cell-Based Inactivated Influenza Vaccine; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Influenza, Human
Interventions: Flu Symptoms; Device
Lead sponsor: Sekisui Diagnostics, LLC; Industry
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Little Rock, Arkansas • Coral Gables, Florida • Lauderdale Lakes, Florida + 11 more

Conditions: Influenza
Interventions: Electronic health record and messaging system; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 2 more

Conditions: Influenza
Interventions: QIVc, TIV1c, TIV2c; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years and older
Enrollment: 2,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 40
States / cities: Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 33 more

Conditions: MAJOR DEPRESSIVE DISORDER
Interventions: INFLUENZA VACCINE, NaCl-saline placebo; Biological · Other
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Search by objective public record fields.

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

Incentives for Influenza Vaccination

Commercially Available Cannabis Products for Immune Support

Memory for Flu Facts and Myths and Effects on Vaccine Intentions

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Influenza Vaccine Post Allogeneic Transplant

A Study to Describe Pediatric Influenza Vaccine Coverage

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)

Study to Eliminate Hib Carriage in Rural Alaska Native Villages

Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Response to Influenza Vaccination in Pediatric Oncology Patients

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza Vaccination

Assessment of the Clinical Performance of the ARROW-FLU System

Electronic Health Records for Health Promotion

H5N1 Mix and Match With MF59

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

Influenza Challenge in Mood Disorders